Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
Holding GDTC?
Track your performance easily
GDTC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.20 - $5.50
Previous Close$2.26
Volume2.69K
Average Volume (3M)13.05K
Market Cap
$26.07M
Enterprise Value$19.65M
Total Cash (Recent Filing)S$9.04M
Total Debt (Recent Filing)S$448.02K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
May 05, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding11,540,000
10 Day Avg. Volume7,635
30 Day Avg. Volume13,055
Standard Deviation0.24
R-Squared0.00008
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.28
Price to Sales (P/S)58.21
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CytoMed Therapeutics Limited News
PremiumCompany Announcements
CytoMed Reaches Milestone with New Cancer Therapy
PremiumCompany Announcements
CytoMed Launches Innovative CAR-T Cell Trial
PremiumCompany Announcements
CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine
PremiumCompany Announcements
CytoMed Therapeutics Reports Interim Financial LossOwnership Overview
39.34% Insiders
0.04% Mutual Funds
0.05% Other Institutional Investors
60.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $1.20 and its highest was $5.50 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
Currently, no data Available
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
CytoMed Therapeutics Limited’s upcoming earnings report date is May 05, 2025 which is in 161 days.
How were CytoMed Therapeutics Limited’s earnings last quarter?
CytoMed Therapeutics Limited released its earnings results on Oct 08, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.01.
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,540,000 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
CytoMed Therapeutics Limited reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
---
CytoMed Therapeutics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.94%
12-Months-Change
Fundamentals
Return on Equity
-26.36%
Trailing 12-Months
Asset Growth
-21.71%
Trailing 12-Months
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors.
---
GDTC Earnings Call
Q2 2024
0:00 / 0:00
---
Technical Analysis
---